Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Bumb, Jan Malte [VerfasserIn]   i
 Enning, Frank [VerfasserIn]   i
 Leweke, F. Markus [VerfasserIn]   i
Titel:Drug repurposing and emerging adjunctive treatments for schizophrenia
Verf.angabe:Jan Malte Bumb, MD, Frank Enning, MD, and F. Markus Leweke, MD
E-Jahr:2015
Jahr:12 Apr 2015
Umfang:19 S.
Fussnoten:Gesehen am 29.11.2017
Titel Quelle:Enthalten in: Expert opinion on pharmacotherapy
Ort Quelle:Abingdon, Oxon : Routledge, Taylor & Francis, 1999
Jahr Quelle:2015
Band/Heft Quelle:16(2015), 7, Seite 1049-1067
ISSN Quelle:1744-7666
Abstract:Introduction: Schizophrenia is a frequent disorder, which substantially impairs patients’ quality of life. Moreover, the burden of illness for patients, their families and for the society, in general, is substantial. Nevertheless, the understanding of the pathophysiology of this syndrome, concise diagnostic methods and more effective and tolerable treatments are still lacking. Thus, innovative approaches and the exploration of new territories are required. Areas covered: An overview of repurposed drugs and emerging treatments for schizophrenia is presented, focusing on randomized, controlled trials and meta-analyses. Expert opinion: Despite many years of drug research, several needs in the treatment of schizophrenia including the safety and tolerability, stage-dependent and personalized approaches, as well as drug delivery and sustainability have not been addressed sufficiently. Given the current failure of a number of mechanistically new drugs, repurposed compounds may serve as alternative and/or adjunctive agents for schizophrenic patients and for treatment refractory patients in particular. Anti-inflammatory drugs (e.g., acetylsalicylic acid, celecoxib and minocycline), as well as N-acetylcysteine, a precursor of the major antioxidant glutathione, hormones (e.g., estrogen, raloxifene and oxytocin), glutamatergic (e.g., glycine and d-serine) and nicotinergic compounds, ‘nutraceuticals’ (e.g., ω-3 fatty acids) and cannabidiol, an endocannabinoidmodulator, represent promising agents in this field.
DOI:doi:10.1517/14656566.2015.1032248
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: http://dx.doi.org/10.1517/14656566.2015.1032248
 Volltext: https://doi.org/10.1517/14656566.2015.1032248
 DOI: https://doi.org/10.1517/14656566.2015.1032248
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:antipsychotics
 emerging drugs
 new mechanisms
 quality of life
 repurposed drugs
 schizophrenia
 treatment resistance
K10plus-PPN:1565863771
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68195726   QR-Code
zum Seitenanfang